Isabelle Debrix
About
In The Last Decade
Isabelle Debrix
16 papers receiving 235 citations
Peers
Comparison fields: 5 of 64
- Oncology 110
- Pulmonary and Respiratory Medicine 83
- Urology 44
- Surgery 41
- Rheumatology 38
Countries citing papers authored by Isabelle Debrix
This map shows the geographic impact of Isabelle Debrix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Debrix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Debrix more than expected).
Fields of papers citing papers by Isabelle Debrix
This network shows the impact of papers produced by Isabelle Debrix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Debrix. The network helps show where Isabelle Debrix may publish in the future.
Co-authorship network of co-authors of Isabelle Debrix
This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Debrix. A scholar is included among the top collaborators of Isabelle Debrix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Debrix. Isabelle Debrix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 2 | |
| 5 | 7 | |
| 6 | 42 | |
| 7 | 5 | |
| 8 | 1 | |
| 9 | 0 | |
| 10 | 115 | |
| 11 | 0 | |
| 12 | Evaluating the differences between fibrin sealants: recommendations from an international advisory panel of hospital pharmacists | 24 |
| 13 | 1 | |
| 14 | [Anticancer drugs off label used of: what do the experts think about?]. | 7 |
| 15 | [Anticancer drugs use evaluation: limits of the approved labeling]. | 2 |
| 16 | 4 | |
| 17 | 3 | |
| 18 | 2 | |
| 19 | 25 | |
| 20 | [Efficacy of the granisetron/solumedrol combination in the control of drug-induced acute nausea and vomiting. Results of a prospective survey]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.